Meeting
2023 ASCO Annual Meeting
Outcomes in pediatric relapsed/refractory anaplastic large cell lymphoma: A multi-institutional retrospective analysis.
Authors
Lianna Jean Marks
Stanford University School of Medicine, Palo Alto, CA
Lianna Jean Marks , Victor Ritter , Liora M. Schultz , Eric J. Lowe , Catherine Aftandilian
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Leukemia/Lymphoma
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 10032)
DOI
10.1200/JCO.2023.41.16_suppl.10032
Abstract #
10032
Poster Bd #
338
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Phase III study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL).
First Author: Anas Younes
Poster
2011 ASCO Annual Meeting
Durable remissions with brentuximab vedotin (SGN-35): Updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).
First Author: B. Pro
Poster
2022 ASCO Annual Meeting
Real-world outcomes of brentuximab vedotin maintenance after autologous stem cell transplant in relapsed/refractory classical Hodgkin lymphoma: Is less enough?
First Author: Charlotte Burton Wagner
Poster
2022 ASCO Annual Meeting
Autologous hematopoietic stem cell transplantation in tandem with anti-CD30 CAR T-cell infusion in relapsed/refractory CD30+ lymphoma.
First Author: Xiuxiu Yang